Anthrogenesis, based in Cedar Knolls, New Jersey, is a biotherapeutics company that has developed proprietary methods for collecting, processing and storing stem cells and other valuable biomaterials derived from human placental tissue. Anthrogenesis is focused on developing and delivering therapies using stem cells sourced from human placental tissue to treat cancers and immunological, metabolic and inflammatory diseases. Anthrogenesis has demonstrated that the human placenta is an abundant source of biotherapies, including early stage stem cells and other biomaterials for organ and tissue repair. Anthrogenesis also operates Lifebank, a state-licensed blood bank that banks stem cell transplant units derived from placental tissue and in some cases, blood from the umbilical cord that is collected immediately after birth.

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.

Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD.

Sorrento Therapeutics is a development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento’s late stage pipeline include Cynviloq™ (paclitaxel in polymeric micelle formulation) currently in a registrational bio-equivalent study versus albumin-bound paclitaxel; and Resiniferatoxin (RTX),which is in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. Sorrento has one of the industry’s most diverse antibody (G-MAB®) library comprised of high-quality, fully human antibodies with a diversity of more than ten trillion (>10^16). Along with its' proprietary conjugation chemistries and novel toxins, Sorrento has all in-house capabilities to generate and develop a new generation of homogenous ADCs with well-defined drug antibody ratios (DAR) in contrast to approved ADCs, which are heterogeneous mixtures with different DARs. These differentiating characteristics may lead to improved ADC stability and pharmacokinetics while reducing off-target effects compared to existing ADCs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases.

Triad Life Sciences, Inc., part of ConvaTec Group Plc, is a company headquartered in Memphis, TN, that manufactures and distributes medical devices. It was founded in 2017 by Russell I. Olsen, he has been the CEO since that date. Triad Life Sciences, Inc. was acquired by ConvaTec Group Plc on March 14, 2022 for $450 million.\nThe company says this about itself: Triad Life Sciences, Inc. is an emerging biotech company focused on developing and commercializing innovative, efficacious and affordable biomaterials for treating complex surgical and chronic wounds. Triad recently received FDA clearance to market InnovaMatrix™, a next generation extracellular matrix (ECM) wound care device. As the first and only FDA cleared placental wound care device, this disruptive technology platform will set the bar for future wound care materials in terms of product reliability, product innovation and best-in-class economics. At Triad Life Sciences, you will find a team of dedicated professionals that possess a fierce resolve, unwavering enthusiasm and commitment to excellence in delivering solutions to uplift and save lives.

Cryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. It operates through the following segments: Cellular Processing and Cryogenic Storage, and Prepacyte CB. The Cellular Processing and Cryogenic Storage segment focuses on the collection and preservation of umbilical cord blood and tissue stem cells for family use. The Prepacyte CB segment refers to the processing technology used to process umbilical cord blood stem cells. The company was founded in 1989 and is headquartered in Oldsmar, FL.

HLI Cellular Therapeutics LLC provides therapeutics services. The company is headquartered in San Diego, CA.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

Part of Pluri, Inc., Pluristem Ltd. is a company headquartered in Haifa, Israel, that provides research and development services in the biotechnology field, especially in stem cell research. The firm was founded by Yoram Nathan Drucker. Pluri, Inc. acquired Pluristem Ltd. on June 23, 2003.

Smith & Nephew PLC designs, manufactures and markets orthopedic devices, sports medicine and ENT technologies, and wound-care solutions. Slightly more than 40% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is a sports medicine and ENT. The remaining 27% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Tian Qing Stem Cell Co., Ltd. engages in the stem cell extraction and storage services. It is mainly engaged in hematopoietic stem cell storage, umbilical cord mesenchymal stem cell storage, adipose stem cell storage, placental tissue storage and other clinical storage businesses. The company was founded on September 11, 2006 and is headquartered in Harbin, China.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Yunnan Heze Southwest Biotechnology Co., Ltd., established on 2010-08-05, Business scope includes stem cell storage technology services;stem cell collection,detection,to prepare,Freezing and Serving;Research and Development of Stem Cell Biotechnology,technology transfer,technical consulting,Technical Services;Research and development of immune cell technology,technology transfer,technical consulting,Technical Services;Research and development of medical testing technology,technology transfer,technical consulting,Technical Services;Research and development of bioelectronic technology,technology transfer,Technical Services;Research and development of cosmetics-related technologies;cosmetic,In vitro diagnostic reagents,Sales of Medical Devices;Genetic data analysis service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Yinfeng Bioengineering Group Co., Ltd., established on 2011-04-19, Business scope includes general items:R&D and application of cell technology;Human stem cell technology development and application;Development of Human Gene Diagnosis and Therapy Technology;Health Consulting Services(Does not include medical services);Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Daily necessities sales;Maternal and baby products sales;Cosmetics Wholesale;Cosmetics Retail.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Class III medical device business;Health food sales;Cosmetic production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Yinfeng Cryogenic Medical Technology Co., Ltd., established on 2016-01-19, The scope of business includes the development of low temperature medical cryopreservation equipment and reagents;Cryo-freezing and cryo-medicine technology development,Technical service and technical consultation;Technology development, production and processing of freeze-dried food.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Develops and manufactures products for the ostomy management, advanced chronic and acute wound care and continence care services